Dr. Stewart Martin |
|
University of Nottingham Molecular Medical Sciences Clinical Oncology Translational Radiation Biology Group HeadAppointed: 1997 University of Nottingham Molecular Medical Sciences Clinical Oncology Associate ProfessorAppointed: 2004 |  |
Mailing AddressUniversity of Nottingham Department of Clinical Oncology City Hospital Nottingham, NG5 1PBUnited Kingdom | Contact Information |
Qualifications
PGCAP, University of Nottingham, 2001.
Ph.D., University of London, Radiation Biology, 1990.
M.Sc., St. Andrews University, Radiation Biophysics, 1986.
Expertise and Research Interests
Current Research Interests:
The mechanism of action of novel anticancer agents for the treatment of ovarian, breast and colorectal cancer.
Redox regulation in cancer (ovarian, breast and colorectal cancer).
Regulation of lymphovascular invasion in breast cancer and melanoma.
Leukocyte (macrophage, dendritic cell and monocyte) and tumour cell (breast and melanoma) adhesion to, and intravasation across, lymphatic and vascular endothelium.
Inflammatory regulation of lymphatic cell biology.
Prognostic significance and involvement of angio- and lymphangiogenesis in the pathophysiology and radiation response of breast cancer.
Expertise:
Cancer Biology / Radiation Biology / Vascular Biology - Translational Research interests
Research History:
Originally trained as a Radiation Biologist at CRC Gray Laboratory (under the supervision of Dr Cliff Murray, Prof. Julie Denekamp and Prof. Klaus Trott) - molecular basis of late normal tissue effects - radiation induced fibrosis (biochemical analysis of collagen metabolism, immunohistochemistry, physiology).
Post-doctoral position with Prof. Mort Elkind at Colorado State University - radiation induced mutagenesis. Studied mutational spectrum induced by low dose rate ionising radiation in mammalian cell lines.
Post-doctoral position with Prof. Eric Hall at Columbia University: Mammalian cell transformation - Several mammalian cell lines were used to study oncogenic transformation induced by a variety of physical and chemical agents. Ionizing radiation, particularly alpha-particles of defined linear energy transfer (LET) and monoenergetic neutrons produced by the Radiological Research Accelerator Facility (RARAF), was the primary agent of interest. SHE, C3H 10T½, Human Uroepithelial Cells (HUC) and Human Epidermal Keratinocytes (RHEK-1) were the cell lines used most frequently. The various steps in the carcinogenic pathway from normal primary (SHE) or immortalised cells (10T½, HUC, RHEK-1) to fully aggressive tumours were monitored both quantitatively and qualitatively by cytogenetic, immunohistochemical and molecular analysis.
Associate Research Scientist at University of Nottingham - Tumour Vascular Biology (with Dr. Cliff Murray): Examination and characterisation of phenotypic and genotypic differences between normal and tumour associated human endothelial cells. Characterisation by immunohistochemical and flow cytometric techniques. Gene expression examined via RT-PCR. Promoter activity of those genes showing up-regulation under tumour conditions was assayed by nuclear run-on techniques. Characterisation of gene promoters was carried out by use of CAT, b-galactosidase or luciferase reporter constructs. A number of transfection techniques, including adenoviral mediated transfection, were used to assay promoter activity and gauge their usefulness for endothelial cell gene therapy strategies utilising enzyme-prodrug methodologies (HSV-tk, cytosine deaminase).
Non-Clinical Lecturer in Oncology, University of Nottingham, School of Molecular Medical Sciences, Department of Clinical Oncology, City Hospital, Nottingham 1997-2003
The mechanism of action of novel anticancer agents for the treatment of ovarian, breast and colorectal cancer.
Redox regulation in cancer (ovarian, breast and colorectal cancer).
Regulation of lymphovascular invasion in breast cancer and melanoma.
Leukocyte (macrophage, dendritic cell and monocyte) and tumour cell (breast and melanoma) adhesion to, and intravasation across, lymphatic and vascular endothelium.
Inflammatory regulation of lymphatic cell biology.
Prognostic significance and involvement of angio- and lymphangiogenesis in the pathophysiology and radiation response of breast cancer.
Expertise:
Cancer Biology / Radiation Biology / Vascular Biology - Translational Research interests
Research History:
Originally trained as a Radiation Biologist at CRC Gray Laboratory (under the supervision of Dr Cliff Murray, Prof. Julie Denekamp and Prof. Klaus Trott) - molecular basis of late normal tissue effects - radiation induced fibrosis (biochemical analysis of collagen metabolism, immunohistochemistry, physiology).
Post-doctoral position with Prof. Mort Elkind at Colorado State University - radiation induced mutagenesis. Studied mutational spectrum induced by low dose rate ionising radiation in mammalian cell lines.
Post-doctoral position with Prof. Eric Hall at Columbia University: Mammalian cell transformation - Several mammalian cell lines were used to study oncogenic transformation induced by a variety of physical and chemical agents. Ionizing radiation, particularly alpha-particles of defined linear energy transfer (LET) and monoenergetic neutrons produced by the Radiological Research Accelerator Facility (RARAF), was the primary agent of interest. SHE, C3H 10T½, Human Uroepithelial Cells (HUC) and Human Epidermal Keratinocytes (RHEK-1) were the cell lines used most frequently. The various steps in the carcinogenic pathway from normal primary (SHE) or immortalised cells (10T½, HUC, RHEK-1) to fully aggressive tumours were monitored both quantitatively and qualitatively by cytogenetic, immunohistochemical and molecular analysis.
Associate Research Scientist at University of Nottingham - Tumour Vascular Biology (with Dr. Cliff Murray): Examination and characterisation of phenotypic and genotypic differences between normal and tumour associated human endothelial cells. Characterisation by immunohistochemical and flow cytometric techniques. Gene expression examined via RT-PCR. Promoter activity of those genes showing up-regulation under tumour conditions was assayed by nuclear run-on techniques. Characterisation of gene promoters was carried out by use of CAT, b-galactosidase or luciferase reporter constructs. A number of transfection techniques, including adenoviral mediated transfection, were used to assay promoter activity and gauge their usefulness for endothelial cell gene therapy strategies utilising enzyme-prodrug methodologies (HSV-tk, cytosine deaminase).
Non-Clinical Lecturer in Oncology, University of Nottingham, School of Molecular Medical Sciences, Department of Clinical Oncology, City Hospital, Nottingham 1997-2003
Other Expertise
Currently organise and administer an MSc course in Oncolgy at University of Nottingham. Course runs as a 1-year full-time option or 2-year part-time option and is open to both basic science graduates and clinicians (or other health care professionals). Details available on:
http://www.nottingham.ac.uk/clinical-oncology/MSc_Oncology/index.htm
The course aims to provide an advanced course of study in the theoretical and practical aspects of the causes and treatment of cancer. The objectives are to provide instruction and training in the theoretical principles of the subjects covered and, through a project and dissertation, to familiarise students with the research environment thereby developing the skills necessary to undertake independent research.
Students successfully completing the course acquire basic research skills combined with an advanced knowledge of Oncological science. They should be able to critically evaluate new advances in cancer research and be familiar with the analytical methods used in its study. Clinicians gain greater understanding of the scientific basis of cancer and its treatment with science graduates developing greater awareness of the clinical aspects of cancer management.
The level of scholarship and education allows students to develop their skills as new information and technology appears and provides the academic achievement to allow some graduates to enter an alternative discipline. It also provides an excellent foundation for entering further studies or a career in research and development.
Member of Scientific Advisory Board, Breast Cancer Campaign (from 2007).
Elected to Executive Committee of British Association for Cancer Research 2001 (Treasurer of BACR from 2002-2007).
Elected as member of University Senate of University of Nottingham 2001-2004.
Member, and Secretary, of British Institute of Radiology's Radiation and Cancer Biology Committee (from March 2002).
Member of Trent Regional Oncology Education Committee (from 1998).
Member of Translational Research Group of EORTC (European Organisation for Research and Treatment of Cancer) Radiotherapy Group.
Member of The Open University Life Sciences Research Degree Sub-Committee (from February 2003).
http://www.nottingham.ac.uk/clinical-oncology/MSc_Oncology/index.htm
The course aims to provide an advanced course of study in the theoretical and practical aspects of the causes and treatment of cancer. The objectives are to provide instruction and training in the theoretical principles of the subjects covered and, through a project and dissertation, to familiarise students with the research environment thereby developing the skills necessary to undertake independent research.
Students successfully completing the course acquire basic research skills combined with an advanced knowledge of Oncological science. They should be able to critically evaluate new advances in cancer research and be familiar with the analytical methods used in its study. Clinicians gain greater understanding of the scientific basis of cancer and its treatment with science graduates developing greater awareness of the clinical aspects of cancer management.
The level of scholarship and education allows students to develop their skills as new information and technology appears and provides the academic achievement to allow some graduates to enter an alternative discipline. It also provides an excellent foundation for entering further studies or a career in research and development.
Member of Scientific Advisory Board, Breast Cancer Campaign (from 2007).
Elected to Executive Committee of British Association for Cancer Research 2001 (Treasurer of BACR from 2002-2007).
Elected as member of University Senate of University of Nottingham 2001-2004.
Member, and Secretary, of British Institute of Radiology's Radiation and Cancer Biology Committee (from March 2002).
Member of Trent Regional Oncology Education Committee (from 1998).
Member of Translational Research Group of EORTC (European Organisation for Research and Treatment of Cancer) Radiotherapy Group.
Member of The Open University Life Sciences Research Degree Sub-Committee (from February 2003).
Future Research
Lymphatic cell biology - with particular reference to tumour metastasis (breast cancer and melanoma).
Prognostic and Predictive Factors in Cancer - particularly relating to response to radio- and chemotherapy.
Combinational therapy - pre-clinical studies of novel agents combined with radio- and chemotherapy.
Pre-clinical evaluation of novel chemotherapeutic agents (particularly in Breast, Ovarian and Colorectal Cancer).
Prognostic and Predictive Factors in Cancer - particularly relating to response to radio- and chemotherapy.
Combinational therapy - pre-clinical studies of novel agents combined with radio- and chemotherapy.
Pre-clinical evaluation of novel chemotherapeutic agents (particularly in Breast, Ovarian and Colorectal Cancer).
Keywords
COS Keywords:
Angiogenesis, Biomedical Research Training, Cancer or Carcinogenesis, Molecular Oncology, Oncology, Radiation Oncology, Vascular Biology.Additional Terms:
Angiogenesis, Breast Cancer, Cancer, Chemotherapy, Lymphatic System, Ovarian Cancer, Radiation.Languages
(Reading, Writing, Speaking)
English: (Fluent, Fluent, Fluent)
French: (Functional, Basic, Basic)
Greek: (Basic, Basic, Basic)
Memberships
American Association for Cancer Research
Association for Radiation Research (UK)
British Association for Cancer Research
British Institute of Radiology
British Microcirculation Society
European Association for Cancer Research
European Society for Therapeutic Radiology and Oncology
Federation of American Societies for Experimental Biology
Higher Education Academy UK
Metastasis Research Society
Radiation Research Society
University and College Union
Previous Positions
1997-2003, Non-Clinical Lecturer,
University of Nottingham,
Molecular Medical Sciences,
Clinical Oncology
1994-1997, Associate Research Scientist,
University of Nottingham,
Clinical Laboratory Sciences,
Clinical Oncology
1992-1994, Associate Research Scientist,
Columbia University,
Centre for Radiation Research
1991-1992, Post-doctoral Research Fellow,
Columbia University,
Centre for Radiation Research
1990-1991, Post-doctoral Research Fellow,
Colorado State University,
Radiation Biology
Funding Received
- Wellcome Trust: Experimental radiation biology irradiation facility, £136,684, 2009 to 2012.
- Knowledge Transfer Partnership Award (Technology Strategy Board): Genomic and transcriptomic anlaysis of formalin fixed paraffin embedded archival breast cancer specimens, £115,737, 2009 to 2011.
- University of Nottingham Institute of Clinical Research: Lymphovascular invasion in melanoma., £4,000, 2008 to .
- Cancer Research UK: Lymphovascular invasion in breast cancer., £82,390, 2008 to 2010.
- British Skin Foundation: Lymphovascular invasion in melanoma, £10,000, 2008 to .
- Mason Medical Research Foundation: Improved prognostic index for colorectal cancer (Principal Investigator: J Simpson, Co-Investigators: LG Durrant, I Spendlove, JH Scholefield, SG Martin and I Mohammad), £10,000, 2008 to 2009.
- Breast Cancer Campaign: Redox proteins in breast cancer, £139,514, 2007 to 2010.
- Biomedical Research Committee, University of Nottingham: Experimental Radiation Biology Irradiation Facility, £20,000.00, 2007 to .
- East Midlands Development Agency (EMDA): Pump-priming award - a proteomic analysis of the action of PMX464 on cancer cells., £6,000, 2006 to .
- Association of International Cancer Research (AICR): Characterising the direct and antiangiogenic effects of AW464, a novel thioredoxin inhibitor, in breast cancer, £74,570.00, 2005 to 2009.
- Cancer Research UK: Masters Course Bursary Fund, £95,650.00, 2005 to .
- European Commission (EC): Oncology Training/ MSc course at Univ. of Nottingham, £95,059.00, 2005 to 2006.
- European Commission (EC): Oncology Training/ MSc course at Univ. of Nottingham, £92,254.00, 2003 to 2004.
- European Commission (EC): Oncology Training/ MSc course at Univ. of Nottingham, £85,362.00, 2001 to 2002.
- Nottingham City Hospital Head & Neck Cancer Research Fund: Predictive value of angiogenic markers in head and neck cancer treated by primary radiotherapy., £36,000.00, 2000 to .
- European Commission (EC): Oncology Training/ MSc course at Univ. of Nottingham, £272,782.00, 1997 to 2000.
Publications
- Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL, Madhusudan S (Jan 2009) Biomarkers of response to therapy in oesophago-gastric cancer., Gut, 58 (1), 127-43
- Stewart Martin, Cliff Murray (2008) Angiogenesis Protocols (Methods in Molecular Biology), 2nd Ed, Humana Press, 364 pages pages, ISBN=1588299074
- Mohammed RA, Ellis IO, Lee AH, Martin SG (Nov 2008) Vascular invasion in breast cancer; an overview of recent prognostic developments and molecular pathophysiological mechanisms., Histopathology
- Mukherjee, A, Martin, SG (2008) The thioredoxin system: a key target in tumour and endothelial cells., British Journal of Radiology, 81, S57-S68
- Mohammed RA, Ellis IO, Elsheikh S, Paish EC, Martin SG (Feb 2008) Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications., Breast cancer research and treatment
- Huber K, Patel P, Zhang L, Evans H, Westwell AD, Fischer PM, Chan S, Martin S (Jan 2008) 2-[(1-Methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation., Molecular cancer therapeutics, 7 (1), 143-51
- Martin, S.G., Morgan, D.A.L. (2008) Radiotherapy and radiosensitisers., Scott-Brown's Otorhinolaryngology, Head and Neck Surgery. 7th ed. Volume 1. Gleeson, M., Browning, G.G, Burton, M.J., Clarke, R., Hibbert, J., Jones, N.S., Lund, V.J., Luxon, L.M., Watkinson,J.C., eds., Hodder Arnold, 47-55 pages (bookchapter)
- Mohammed RA, Martin SG, Gill MS, Green AR, Paish EC, Ellis IO (Dec 2007) Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences., The American journal of surgical pathology, 31 (12), 1825-33
- Mukherjee A, Huber K, Evans H, Lakhani N, Martin S (Aug 2007) A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell lines., British journal of pharmacology, 151 (8), 1167-75
- Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG (Apr 2007) Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis., British journal of cancer, 96 (7), 1092-100
- Martin S (Feb 2007) New Agents in Clinical Oncology. 24 November 2006, London, UK., IDrugs : the investigational drugs journal, 10 (2), 99-101
- Martin SG, Orridge C, Mukherjee A, Morgan DA (Feb 2007) Vascular endothelial growth factor expression predicts outcome after primary radiotherapy for head and neck squamous cell cancer., Clinical oncology (Royal College of Radiologists (Great Britain)), 19 (1), 71-6
- Mukherjee A, Martin SG (Nov 2006) In vitro cytotoxicity of Phortress against colorectal cancer., International journal of oncology, 29 (5), 1287-94
- Mukherjee A, Westwell AD, Bradshaw TD, Stevens MF, Carmichael J, Martin SG (Jan 2005) Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study., British journal of cancer, 92 (2), 350-8
- SG Martin, DAL Morgan and C Orridge, Correlation of angiogenic growth factor expression and prognosis in patients treated by primary radiotherapy for advanced head and neck cancer, International Journal of Radiation Oncology, Biology, Physics, 55(2), 525, 2003
- SG Martin, DAL Morgan and C Orridge, Altered radio-responsiveness of breast cancer cells by hormonal agents – an in vitro study, International Journal of Radiation Oncology, Biology, Physics, 55(2), 487, 2003
- A. Mukerjee, S.G. Martin, T.D. Bradshaw, A.D. Westwell, M.F.G. Stevens and J. Carmichael, In vitro anti-tumour and anti-angiogenic activity of AW464 (NSC 706704), a novel quinol, British Journal of Cancer, 86(Supp I), S108 (P245), 2002
- S.G. Martin, Transfection and transduction of primary human endothelial cells, Methods in Molecular Medicine: Angiogenesis protocols., Murray, JC (Ed)(Humana Press), 2001
- SG Martin and JC Murray, Gene transfer systems for human endothelial cells, Advanced Drug Delivery Reviews, 41, 223-233, 2000
Profile Details
Last Updated: 1/6/2009
COS Expertise ID #346812
Reference this profile directly: http://myprofile.cos.com/stewartgmartin
Individual Expertise profile of Stewart Martin, Copyright Stewart Martin.
© COS ExpertiseTM, 2010, ProQuest LLC All rights reserved.